1. Taiwan Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Great Novel Therapeutics Biotech & Medicals Corp.

Great Novel Therapeutics Biotech & Medicals Corp.

TTPEX:7427
60.50
TWD
-0.70
(-1.14%)
2.11BMarket Cap
Great Novel Therapeutics Biotech & Medicals Corp.
TPEX:7427
(Taipei Exchange)

Recent

price

60.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.21
0.01
- -
0.02
0.02
0.13
0.04
0.03
- -
Revenue per Share
-2.62
-1.78
-1.59
-1.37
-1.92
-1.6
-2.42
-2.15
- -
Basic EPS, GAAP
-2.46
-3.06
-2.8
-2.37
-2.7
-1.95
-1.85
-2.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.45
2.4
4.31
7.45
10.24
12.75
13.81
11.23
14.24
Book Value per Share
2.21
1.01
2.59
4.28
7.42
12.05
13.2
10.63
13.75
Tangible Book Value per Share
14
17
20
26
29
38
43
45
45
Basic Weighted Avg Shares
3
- -
- -
1
1
5
2
1
- -
Sales/Revenue/Turnover
-1,299.68
-34,610.23
- -
-5,796.98
-10,636.67
-1,357.11
-6,685.28
-8,260.91
- -
Operating Margin (%)
1
1
1
1
2
4
7
8
- -
Depreciation Expense
-36
-30
-31
-36
-56
-61
-105
-97
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,252.36
-33,948.86
- -
-5,691.59
-10,329.44
-1,257.67
-6,226.94
-8,089.05
- -
Profit Margin (%)
58
23
62
104
239
470
577
447
697
Working Capital
- -
- -
- -
- -
- -
11
7
4
3
LT Debt
69
67
121
208
361
534
633
503
754
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-44.08
-33.34
-21.8
-19.6
-13.63
-17.97
-17.16
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
3
3
4
LT Borrowings
- -
- -
- -
LT Finance Leases
6
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
53
Market Capitalization
1,516
1,361
2,106

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
526
466
724
Cash, Cash Equivalents & STI
501
448
699
Accounts Receivable, Net
- -
- -
3
Inventories
3
7
9
Total Current Liabilities
17
19
27
Payables & Accruals
- -
- -
- -
ST Debt
3
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38.41%
-20.58%
Free Cash Flow
- -
11.11%
13.37%
Net Income, GAAP
- -
28.9%
-7.1%
Sales/Revenue/Turnover
- -
- -
-28.49%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.42
2025
- -
- -
-2.15
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) (7427.TWO) develops innovative oral drugs for cancer immunotherapy targeting advanced and refractory cancers, including epigenetic modulators, tumor microenvironment regulators, and immune-regulating multi-kinase inhibitors; core products encompass the licensed oral anti-cancer agent Tucidinostat (trade name Kepida or 剋必達), approved in Taiwan for HR+/HER-2- advanced breast cancer and under review for relapsed/refractory peripheral T-cell lymphoma, alongside proprietary pipeline candidates such as GNTbm-38, an epigenetic immune activator reprogramming the tumor microenvironment to enhance T-cell infiltration and immune memory, and GNTbm-TKI, a multi-tyrosine kinase inhibitor targeting ROS1, BTK, and ATM kinases for synergistic immunotherapy combinations. Founded in 2013 and headquartered at No. 508, Section 7, Zhongxiao East Road, Taipei City, Taiwan, the company operates primarily in the biotechnology sector with a focus on Taiwan, China, the US, and global markets through worldwide patent protections and clinical development strategies emphasizing orphan indications and solid tumors. Recent developments include the commercial launch of Kepida in Taiwan targeting a TWD 35-50 billion market for second-line HR+/HER-2- breast cancer treatment, achievement of national health insurance reimbursement approval for Kepida in November 2025, a manufacturing partnership with Taiyo for GNTbm-38 production to support US, China, and Taiwan IND applications planned for early 2026, preclinical data presentations on GNTbm-38 at the 2025 ASCO Annual Meeting demonstrating superior efficacy in combination with TKIs and PD-1 inhibitors against cold tumors, and on GNTbm-TKI at the 2025 ESMO Annual Meeting highlighting potent immune activation.